Certain correction studies indicate that roxadustat ameliorates anemia in patients undergoing HD regardless of baseline C-reactive protein levels, and its dosage requirements are less affected by inflammation compared to ESAs [54,55]. This evidence concerns the gene CRP and anemia (phenotype).